{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "PART 862 -- CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES" in comments (approximate match)
Status:
First approved in 1955
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Menopur by Ferring Pharmaceuticals [Canada]
Source URL:
First approved in 2016
Source:
NADA141431
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT01715493: Phase 4 Interventional Completed Chronic Obstructive Pulmonary Disease
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 346
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT01339299: Phase 4 Interventional Completed Controlled Ovarian Stimulation
(2009)
Source URL:
First approved in 1975
Source:
BLA021663
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00898534: Phase 4 Interventional Completed Type 1 Diabetes Mellitus
(2003)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 1942
Class:
STRUCTURALLY DIVERSE
